Secor Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Secor Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,127	Closed	-$109K	–	517
2018 Q1	$109K	Buy	+3,127	New	+$121K	0.01%	489
2017 Q1	–	Sell	-4,806	Closed	-$255K	–	474
2016 Q4	$255K	Buy	+4,806	New	+$273K	0.03%	422
2016 Q2	–	Sell	-2,886	Closed	-$164K	–	592
2016 Q1	$164K	Buy	+2,886	New	+$325K	0.02%	564

Other funds holding CLDX

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Secor Capital Advisors's CLDX Position: Q2 2018 in Review

Secor Capital Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2018, closing a stake of 3,127 shares — an estimated $109K sold.

Secor Capital Advisors first reported a position in CLDX in Q1 2016 and held it in 3 quarters. The position peaked at $255K in Q4 2016. 102 funds tracked by Wall St. Rank hold CLDX as of Q2 2018.

Secor Capital Advisors reported no remaining Celldex Therapeutics position as of Q2 2018 after selling out during the quarter.
Secor Capital Advisors sold 3,127 Celldex Therapeutics shares in Q2 2018, an estimated $109K.
Secor Capital Advisors first reported a position in Celldex Therapeutics in Q1 2016 and held it in 3 quarters.
Secor Capital Advisors's Celldex Therapeutics position peaked at $255K in Q4 2016.
102 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2018.

Based on Secor Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.